MELBOURNE, Australia--(BUSINESS WIRE)--Australian biotechnology company Avexa (ASX:AVX) announced today further information relating to its Phase IIb clinical trial on apricitabine (ATC) as presented by Dr Pedro Cahn to the International AIDS Society (IAS) meeting in Sydney yesterday afternoon. Dr Cahn is not only one of Avexa’s lead investigators for ATC but is also the President of the International AIDS Society. Dr Cahn’s talk was titled “Superior Activity of Apricitabine in treatment experienced HIV-1 infected patients with M184V and NRTI resistance.”